FINWIRES · TerminalLIVE
FINWIRES
Eli Lilly and Company

Eli Lilly and Company

$LLY
NYSEHealthcare

147 stories mentioning Eli Lilly and CompanyUpdated 2h ago

Eli Lilly trades amid a proposed permanent CMS Medicare drug price negotiation framework; an executive sold $2.88 million in shares per an SEC filing.

Sectors

Sector Update: Healthcare Stocks Gain Thursday Afternoon

Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 1.8% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2%.The iShares Biotechnology ETF (IBB) was down 0.4%.In corporate news, UnitedHealth (UNH) shares rose 3.3% after it posted higher Q2 adjusted earnings and revenue and raised its 2026 adjusted EPS outlook.AtaiBeckley (ATAI) shares surged 33% after Eli Lilly (LLY) said it agreed to acquire the clinical-stage biopharmaceutical company for up to $3.8 billion. Lilly was up 1.3%.Abbott Laboratories (ABT) lifted its full-year earnings outlook on Thursday as the healthcare firm reported Q2 results above market estimates. Abbott shares jumped 11%.

$ABT$ATAI$LLY$UNH
Eli Lilly to Acquire AtaiBeckley for Up to $3.8 Billion to Expand Neuroscience Pipeline
US Markets

Eli Lilly to Acquire AtaiBeckley for Up to $3.8 Billion to Expand Neuroscience Pipeline

AtaiBeckley (ATAI) shares surged more than 30% on Thursday after Eli Lilly (LLY) said it agreed to acquire the clinical-stage biopharmaceutical company for up to $3.8 billion.The purchase price comprises $2.8 billion in upfront cash and about $1 billion in contingent value rights, the pharmaceutical giant said Thursday.New York-based AtaiBeckley is developing rapid-acting therapies for mental health conditions, with its BPL-003 lead program currently in phase 3 development as an intranasal therapy for treatment-resistant depression.Under the agreement, Eli Lilly will pay $6.75 per share in cash upon closing and up to $2.50 per share in CVRs.The CVR payment includes $1 upon starting a phase 3 trial for VLS-01, a dissolving oral film targeting treatment-resistant depression, within four years of closing and another $1 upon US regulatory approval and Drug Enforcement Administration rescheduling of the drug within seven years. The remaining $0.50 is tied to US regulatory clearance and rescheduling of BPL-003, within five years."Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," Carole Ho, president of Lilly Neuroscience, said in a statement. "Advancing AtaiBeckley's investigational therapies gives us a real chance to change that."Earlier this year, Eli Lilly agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, Kelonia Therapeutics for up to $7 billion, Orna Therapeutics for up to $2.4 billion, and three vaccine developers, Curevo, Vaccine Company, and LimmaTech Biologics for up to $1.5 billion, $1.55 billion, and $780 million, respectively.In April, the drugmaker raised its full-year outlook and reported better-than-expected first-quarter results. The company's second-quarter results are scheduled for Aug. 5.AtaiBeckley shares rose 33% in recent Thursday trading, while Eli Lilly was up 1.4%.Price: $7.16, Change: $+1.80, Percent Change: +33.49%

$ATAI$LLY
Sectors

Sector Update: Healthcare Stocks Rise Pre-Bell Thursday

Healthcare stocks were rising pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.2% higher and the iShares Biotechnology ETF (IBB) up 0.5%.UnitedHealth Group (UNH) stock was up more than 7% after the company posted higher Q2 adjusted earnings and revenue, and raised its 2026 adjusted EPS outlook.Abbott Laboratories (ABT) shares were up more than 5% after the company reported higher Q2 adjusted earnings and revenue, and raised its 2026 adjusted EPS guidance.Eli Lilly (LLY) has agreed to acquire AtaiBeckley (ATAI) for $2.8 billion in cash plus potential milestone payments of up to $1.0 billion, the companies said. AtaiBeckley stock was up more than 33% pre-bell.

$ABT$ATAI$IBB$LLY$UNH$XLV
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.1%.The iShares Biotechnology ETF (IBB) added 0.5%.In corporate news, Novo Nordisk (NVO) shares gained 2.9% after it said Wednesday the European Commission granted marketing authorization for its Wegovy pill for the treatment of adults with obesity or overweight with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.Elevance Health (ELV) reported sequential and annual declines in its Q2 memberships, although the health insurer lifted its full-year earnings outlook and recorded an unexpected year-over-year revenue increase in the previous three-month period. The shares fell past 9%.Veradermics (MANE) shares jumped 12% after the company said its VDPHL01 achieved rapid onset of hair growth with the majority of participants in a phase 2 clinical trial of females with mild-to-moderate pattern hair loss.Eli Lilly-backed (LLY) AdvanCell has raised $315 million from its Series D financing, with participating investors such as Bain Capital and Fidelity Management & Research, Bloomberg reported. Lilly shares were fractionally higher.

$ELV$LLY$MANE$NVO
Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3%.The iShares Biotechnology ETF (IBB) added 0.3%.In corporate news, Novo Nordisk (NVO) shares rose 2.5% after it said Wednesday the European Commission granted marketing authorization for its Wegovy pill for the treatment of adults with obesity or overweight with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.Elevance Health (ELV) reported sequential and annual declines in its Q2 memberships, although the health insurer lifted its full-year earnings outlook and recorded an unexpected year-over-year revenue increase in the previous three-month period. The shares fell past 8%.Johnson & Johnson (JNJ) raised its full-year outlook on Wednesday after reporting better-than-expected Q2 results, driven by growth in its innovative medicine and medical device businesses. Its shares were still down 1.7%.Eli Lilly-backed (LLY) AdvanCell has raised $315 million from its Series D financing, with participating investors such as Bain Capital and Fidelity Management & Research, Bloomberg reported. Lilly shares shed 0.4%.

$ELV$JNJ$LLY$NVO
Wire

Eli Lilly Wins Full FDA Approval for Selpercatinib in Solid Tumors

Eli Lilly and Company (LLY) on Tuesday received traditional approval from the US Food and Drug Administration for its drug selpercatinib, Retevmo, to treat adult and pediatric patients two years and older with locally advanced or metastatic solid tumors carrying a RET gene fusion, a genetic alteration that can drive tumor growth.The approval applies to patients who have progressed on prior treatment or have no satisfactory alternative options, as detected by an FDA-approved test.The drug previously held accelerated approval for this indication, the notice said.In a trial of 75 patients with RET fusion-positive tumors outside of lung and thyroid cancer, the drug showed a 47% overall response rate, or share of patients whose tumors shrank significantly, with a median response duration of 24.5 months.The FDA approved the application two months ahead of schedule, and the drug holds orphan drug designation for this tissue-agnostic indication, meaning it applies regardless of where the tumor originated.Price: $1155.18, Change: $-26.69, Percent Change: -2.26%

$LLY
Wire

UBS Adjusts Eli Lilly Price Target to $1,425 From $1,250, Maintains Buy Rating

Eli Lilly (LLY) has an average rating of overweight and mean price target of $1,296.46, according to analysts polled by FactSet.Price: $1191.61, Change: $+3.03, Percent Change: +0.25%

$LLY
Wire

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday.Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) remain its top picks.Bank of America raised its price targets on AbbVie to $276 from $234, Johnson & Johnson (JNJ) to $263 from $254 and Eli Lilly to $1,334 from $1,251.The analysts lowered targets on Bristol Myers Squibb (BMY) to $66 from $67, Pfizer (PFE) to $26 from $27 and United Therapeutics (UTHR) to $613 from $620.Price: $123.45, Change: $-1.63, Percent Change: -1.30%

$ABBV$BMY$IONS$JAZZ$JNJ$LLY$MRK$PFE$UTHR
Wire

BofA Securities Adjusts Eli Lilly Price Target to $1,334 From $1,251

Eli Lilly (LLY) has an average rating of overweight and mean price target of $1,283.12, according to analysts polled by FactSet.Price: $1189.74, Change: $-27.22, Percent Change: -2.24%

$LLY
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Wednesday afternoon, with the NYSE Healthcare Index down 0.9% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.1%.The iShares Biotechnology ETF (IBB) fell 1.2%.In corporate news, HCA Healthcare (HCA) shares dropped nearly 3% after Barclays downgraded the stock to equal weight from overweight and cut its price target to $427 from $496.Eli Lilly (LLY) is poised to outpace Q2 consensus sales estimates as strong volume uptake of its weight-loss drug Zepbound and Mounjaro diabetes treatment drives franchise performance, RBC said in a note. RBC raised its price target to $1,500 from $1,250. Lilly shares were down 1.5%.AstraZeneca (AZN) and Daiichi Sankyo are in advanced talks with England's drug pricing regulator to make the breast cancer medicine Enhertu available to some patients, Bloomberg reported. AstraZeneca shares were shedding 1.8%.Universal Health Services (UHS) shares were down over 3% after Barclays downgraded the company's stock to equal-weight from overweight and adjusted the price target to $179 from $238.

$AZN$HCA$LLY$UHS
Wire

Eli Lilly Could Deliver 'Beat-and-Raise' Quarter, Truist Says

Eli Lilly (LLY) could deliver a "beat-and-raise" second quarter, driven by US prescription growth for Zepbound and Mounjaro, Truist Securities said in a note on Wednesday."We maintain high conviction in Lilly's incretin portfolio," the report said. The Q2 results are due Aug. 5.While current growth stems from Mounjaro/Zepbound, the note pointed to "substantial" potential for Foundayo, its oral obesity treatment, and retatrutide to expand the patient basis."Despite record-shattering revenue, we believe the market remains conservative on the ultimate obesity TAM," the note said. "LLY is well-positioned to capture additional market share over the next decade."Truist raised its price target to $1,370 from $1,281 while keeping its buy rating.Price: $1225.66, Change: $-9.90, Percent Change: -0.80%

$LLY
Sectors

Sector Update: Healthcare Stocks Lower Wednesday Afternoon

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 0.8%.The iShares Biotechnology ETF (IBB) fell 1.5%.In corporate news, Eli Lilly (LLY) is poised to outpace Q2 sales consensus estimates as strong volume uptake of its weight-loss drug Zepbound and Mounjaro diabetes treatment drive franchise performance, RBC said in a note. RBC raised its price target to $1,500 from $1,250. Lilly shares were down 1.2%.AstraZeneca (AZN) and Daiichi Sankyo are in advanced talks with England's drug pricing regulator to make the breast cancer medicine Enhertu available to some patients, Bloomberg reported. AstraZeneca shares were shedding 1.8%.Tvardi (TVRD) said Tuesday its phase 1 study confirmed rapid prodrug conversion of TTI-109 to TTI-101, producing nearly identical plasma levels at molar-equivalent doses, and validating its prodrug design. Raymond James upgraded the stock to outperform from market perform. Shares surged 55%.

$AZN$LLY$TVRD
Sectors

Sector Update: Healthcare

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.8%.The iShares Biotechnology ETF (IBB) fell 1.5%.In corporate news, Eli Lilly (LLY) is poised to outpace Q2 sales consensus estimates as strong volume uptake of its weight-loss drug Zepbound and Mounjaro diabetes treatment drive franchise performance, RBC Capital Markets said in a note. The firm raised its price target on Lilly's stock to $1,500 from $1,250. Lilly shares were down 0.8%.

$LLY
Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says
US Markets

Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says

Major US biopharmaceutical companies' performance in the second half of the year is likely to be driven largely by fundamentals, as the focus shifts away from economic factors, Morgan Stanley said in a note e-mailed Wednesday.The investment firm revised its price targets for several biopharma stocks it covers ahead of the latest earnings season."The macro has been a key driver of large-cap biopharma performance over the first half of the year," the brokerage said in a note to clients. "Looking into the second half, we expect fundamentals to be more of a driver. We prefer stocks with upside from product cycles and/or pipeline catalysts."Morgan Stanley raised its price target for Eli Lilly (LLY) to $1,347 from $1,344. It expects second-quarter earnings per share of $9.06 for the pharmaceutical giant, compared with Wall Street's estimate of $8.80. The firm projects revenue of $20.78 billion, while the Street is looking for $20.47 billion.The firm expects Johnson & Johnson (JNJ) to deliver a second-quarter beat, with EPS projected at $2.90 and sales at $25.46 billion. Morgan Stanley raised its price target on the stock to $284 from $283.Pfizer's (PFE) second-quarter EPS is seen at $0.69, while the Street is looking for $0.68, according to the note. Revenue is projected at $14.29 billion, while the Street is eyeing $14.44 billion.Moderna's (MRNA) new price target is $39, up from $33 previously. The drugmaker is expected to report a second-quarter loss of $1.85 a share on revenue of $172 million versus the Street's views for a $2.06 loss and sales of $102 million, according to Morgan Stanley.The price target for the Abbvie (ABBV) stock moved to $279 from $278, with Morgan Stanley expecting the company's second-quarter revenue to be ahead of consensus and guidance at $16.88 billion, while EPS is seen at $3.71 versus the Street's forecast of $3.76.Morgan Stanley lowered its price target for Gilead Sciences (GILD) to $166 from $168. The brokerage is projecting a second-quarter loss per share at $7.34, while the Street is looking for a $7.31 loss. Revenue is expected at $7.36 billion, below the $7.41 billion consensus, according to the note.Price: $1228.54, Change: $-7.02, Percent Change: -0.57%

$ABBV$GILD$JNJ$LLY$MRNA$PFE
Wire

Update: Truist Securities Raises Price Target on Eli Lilly to $1,370 From $1,281, Keeps Buy Rating

(Updates to include Truist Securities commentary).Truist Securities raised its price target Eli Lilly (LLY) to $1,370 from $1,281, expecting a potential Q2 beat-and-raise.The pharmaceutical company has strong U.S. script growth for Zepbound and Mounjaro, offset by slower-than-expected Foundayo growth, while maintaining high conviction in the company's incretin portfolio, analysts led by Srikripa Devarakonda wrote in a Wednesday note.Although current growth stems from Mounjaro and Zepbound, there is meaningful upside from Foundayo, particularly in the international market, and from retatrutide as the company expands its patient base, the analysts mentioned.Eli Lilly has an average rating of overweight and mean price target of $1,283.12, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $1228.16, Change: $-7.40, Percent Change: -0.60%

$LLY
Wire

Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says

Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday.As of July 6, the NYSE Arca Pharmaceutical Index has gained 11% and the Nasdaq Biotechnology Index has added 18%, compared with a 10% gain for the S&P 500 Index, with recent stock performance driven more by changes in valuation multiples than by earnings estimate revisions, the investment bank said.Morgan Stanley said its US Equity Strategy team expects the sector to benefit from broader market leadership. Biotech remains one of the most rate-sensitive sectors, and historically, the sector has delivered nearly 20% annualized returns during falling-rate environments, according to the note.In addition, merger and acquisition activity remains healthy, with several $5 billion to $10 billion deals recently announced, including AbbVie (ABBV) purchasing Apogee (APGE), and Vertex Pharmaceuticals (VRTX) buying Crinetics Pharmaceuticals (CRNX), the investment bank said.Morgan Stanley adjusted its price targets on Biogen (BIIB) to $222 from $224, Amgen (AMGN) to $333 from $340, Gilead Sciences (GILD) to $166 from $168, AbbVie to $279 from $278, Moderna (MRNA) to $39 from $33, BioNTech (BNTX) to $119 from $126, Regeneron Pharmaceuticals (REGN) to $730 from $788, Johnson & Johnson (JNJ) to $284 from $283, and Eli Lilly (LLY) to $1,347 from $1,344.Shares of Biogen, Amgen, Gilead, AbbVie, Moderna, BioNTech, Regeneron, Johnson & Johnson, and Eli Lilly were down 2%, 0.1%, 0.8%, 0.4%, 7%, 1.9%, 1.9%, 0.4%, and 0.5% respectively, in Wednesday trading.Price: $201.67, Change: $-4.03, Percent Change: -1.96%

$ABBV$AMGN$APGE$BIIB$BNTX$CRNX$GILD$JNJ$LLY$MRNA$REGN$VRTX
Eli Lilly Weight-Loss, Diabetes Franchise to Drive Second Quarter Sales Beat, RBC Says
US Markets

Eli Lilly Weight-Loss, Diabetes Franchise to Drive Second Quarter Sales Beat, RBC Says

Eli Lilly (LLY) is poised to outpace second-quarter sales consensus estimates as strong volume uptake of its weight-loss drug Zepbound and Mounjaro diabetes treatment drive franchise performance, RBC Capital Markets said in a note Wednesday.The brokerage expects second-quarter revenue of $20.74 billion, ahead of its previous estimate of $20.32 billion and topping the $20.51 billion consensus. Zepbound sales during the quarter are expected to reach $4.81 billion against the $4.57 billion consensus, while Mounjaro revenue is expected to hit $9.34 billion compared with Wall Street estimates of $8.79 billion.The strength in sales of these drugs will offset expected pricing headwinds and lower sales of older products including breast cancer treatment Verzenio, plaque psoriasis treatment Taltz and type 2 diabetes drug Trulicity, according to the note."(Most favored nation) pricing in Medicare remains in effect throughout 2026, predominantly weighing on late-lifecycle products including Taltz, Trulicity, Verzenio and Forteo," RBC analysts Trung Huynh and Justin Burns said.The firm raised its price target on Lilly's stock to $1,500 from $1,250 due to "continued outperformance" of Mounjaro and Zepbound and increased earnings per share estimates for 2026 and 2027 to $37.10 and $49.33 from $36.24 and $42.89."With higher costs we are in line with consensus on (second quarter) earnings," Huynh and Burns wrote. "We anticipate another guidance raise, though not as much as the (first quarter) increase in sales or earnings per share."The drugmaker is scheduled to report its second-quarter financial results Aug. 5.Eli Lilly shares were down 0.4% in Wednesday trading and have gained 14% this year.Price: $1237.64, Change: $+2.08, Percent Change: +0.17%

$LLY
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1.4%.In corporate news, Vertex Pharmaceuticals (VRTX) agreed to buy endocrine disease drugmaker Crinetics Pharmaceuticals (CRNX) for a total equity value of about $10 billion. Crinetics shares jumped 98%, and Vertex was down 1.2%.Eli Lilly (LLY) Canada said Tuesday that Health Canada has approved Mounjaro for pediatric patients aged 10 to 17 with type 2 diabetes. Lilly shares rose 2.7%.Vera Therapeutics' (VERA) Trutakna has been approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy, the US Food and Drug Administration said in a Tuesday statement. Vera Therapeutics shares jumped by more than 7%.AstraZeneca (AZN) has signed an agreement to access Helix's genomic datasets to support research for drug discovery and development, Helix said Tuesday. AstraZeneca shares added 1.4%.

$AZN$CRNX$LLY$VERA$VRTX
Wire

Market Chatter: Eli Lilly, Regeneron Among First Companies in FDA PreCheck Pilot Program

Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN) are among the first seven companies selected by the U.S. Food and Drug Administration for a pilot program aimed at accelerating reviews of new domestic manufacturing facilities, CNBC reported Monday, citing FDA spokesperson Benjamin Nichols.The other participants in the FDA's PreCheck pilot program are Amneal Pharmaceuticals (AMRX), Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin, the report said.The program allows regulators to begin reviewing new manufacturing facilities while they are still under construction, which the agency estimates could save companies up to 14 months, according to the report.Eli Lilly, Regeneron and FDA did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $1228.24, Change: $+20.12, Percent Change: +1.67%

$AMRX$LLY$REGN
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Friday afternoon, with the NYSE Healthcare Index rising 2.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.5%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Jaypirca to treat adults with chronic lymphocytic leukemia across all lines of therapy. Lilly shares popped 7%.Johnson & Johnson (JNJ) shares gained 4% after the company said Friday that a European Medicines Agency committee recommended expanding Tecvayli's approval in combination with daratumumab for adults with relapsed or refractory multiple myeloma who have received at least one prior therapy.Cumberland Pharmaceuticals (CPIX) shares jumped past 9% after the company presented updated phase 2 results showing additional evidence that ifetroban may help protect heart function in patients with Duchenne muscular dystrophy.Acadia Pharmaceuticals (ACAD) shares climbed nearly 8% after it said the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion of Daybu following a re-examination procedure, recommending approval of the drug to treat neurobehavioral symptoms of Rett syndrome in patients aged five and older.

$ACAD$CPIX$JNJ$LLY

Showing 21-40 of 147

Track with the FINWIRES app suite

FolioX
FolioX
Track Eli Lilly and Company in your portfolio
WheelAI
WheelAI
Analyze Eli Lilly and Company options with the wheel strategy
StockInsider
StockInsider
See market sentiment on Eli Lilly and Company